Risk of Head and Neck Cancer in Patients With Prior Hematologic Malignant Tumors

Abstract

IMPORTANCE More than 1.3 million people in the United States have a hematologic malignant tumor currently or in remission. Previous studies have demonstrated an increased risk of secondary neoplasms in patients with hematologic malignant tumors, but research specifically on the risk of head and neck solid tumors in patients with prior hematologic malignant tumors is limited. OBJECTIVES To examine a possible association between prior hematologic malignant tumors and risk of head and neck cancer and to assess the overall survival (OS) among these patients. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis used the Veterans Affairs (VA) Corporate Data Warehouse (CDW) to identify patients with diagnoses of hematologic malignant tumors and head and neck cancers. All patients in the VA CDW with a birthdate

Global thyroid cancer incidence trend and age-period-cohort model analysis based on Global Burden of Disease Study from 1990 to 2019

“…These patients are overdiagnosed, which caused 90% of new cases in South Korea, 70% in the United States, Italy, France and Australia, and about 50% in Japan and England (24). The evidence supporting the overdiagnosis hypothesis includes: (1) The increase in the incidence of TC is accompanied by a stable or decreasing death rate (16,25,26); (2) The detection of small-sized tumors increased (27,28); (3) The number of new cases of TC is closely related to the number of examinations by ultrasound, CT and other diagnostic techniques (29, 30). However, there are also evidences that challenge the view of overdiagnosis: (1) The detection of large tumors is also increasing, not only small tumors (31,32); (2) Although the overall death rate remained stable, the mortality of advanced tumors really increased (33,34); (3) Molecular genetic characteristics of TC such as BRAF and RAS mutations are changing with time (35).…”

A Rare Case of Dual Metachronous Primary Malignancies, Chronic Myeloid Leukemia, and Tongue Carcinoma in a Patient With Long-Standing Systemic Lupus Erythematosus: A Case Report and Review of Literature

“…In addition, studies have shown that TKI-treated CML patients have an increased risk of developing secondary malignancies with a predisposition to specific organs, including the head and neck, cervix, and prostate [7][8][9]. Moreover, a retrospective analysis using the Veterans Affairs (VA) Corporate Data Warehouse (CDW) suggested that prior HM was negatively associated with survival among patients with second primary head and neck squamous cell carcinoma (SCC) [10].…”

Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer

“…The role of the immune system in tumor regulation is particularly evident in the immunocompromised. Iatrogenic solid organ transplant, diabetes, autoimmunity requiring immunosuppressive therapy, HIV and hemoproliferative malignant disease or disorders and aging, are all associated with an increased risk of developing head and neck cancer (HNC) and worse outcomes [1][2][3][4][5][6][7][8][9][10][11]. Proliferating tumors utilize many forms of immunosuppression to tip the balance of immunoediting toward tumor progression [12].…”